Lirequinil

This classification denotes a sedative and hypnotic with the molecular formula C26H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VUW1087AD, chemically known as (3s)-1-((10-chloro-6,7-dihydro-4-oxo-3-phenyl-4h-benzo(a)quinolizin-1-yl)carbonyl)-3-ethoxypyrrolidine. but generally known as lirequinil, which bears US NIH Compound Identifier 3045375. European Medicines Agency schedules Lirequinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08529MIG. The term LIREQUINIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). LIREQUINIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lirequinil under HS 29337900 and SITC 51561. As of Q4 2014, LIREQUINIL remains the US FDA Preferred Term for this commodity. Lirequinil bears US NLM identifiers UMLS ID C2825299 and NCI Concept Code C80668. SMILES: CLC1CC2C3N(CCC2CC1)C(=O)C(CC3C(=O)N1CC(OCC)CC1)C1CCCCC1.